Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5A | P29375 | 8/20 | 0.38 |
| ▸ | RET | P07949 | 2/20 | 0.33 |
| ▸ | MAP3K5 | Q99683 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23137869 | 0.92 | KDM5A (0.37) | KDM5ARET | |
| SCHEMBL23136939 | 0.92 | KDM5A (0.37) | KDM5ARET | |
| SCHEMBL23137858 | 0.91 | KAT5 (0.36) | KDM5ARET | |
| SCHEMBL28794635 | 0.87 | KDM5A (0.35) | KDM5ARET | |
| SCHEMBL23865452 | 0.80 | — | — | |
| SCHEMBL23223095 | 0.79 | ACHE (0.33) | KDM5AMAP3K5 | |
| SCHEMBL23136940 | 0.76 | USP19 (0.30) | — | |
| SCHEMBL21733948 | 0.73 | IRAK4 (0.30) | — | |
| SCHEMBL20793157 | 0.72 | — | — | |
| SCHEMBL20796826 | 0.69 | MAP3K5 (0.39) | MAP3K5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124496-B2 | Imidazolidine compounds | ELI LILLY AND COMPANY (US) | 2021-09-21 | — | — | US | disclosed |
| US-11117891-B2 | Isoquinolin and naphthydrin compounds | ELI LILLY AND COMPANY (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | Seal Rock Therapeutics, Inc. | 2021-03-25 | — | — | US | disclosed |
| US-20210061785-A1 | IMIDAZOLIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2021-03-04 | — | — | US | disclosed |
| US-20200062751-A1 | ISOQUINOLIN AND NAPHTHYDRIN COMPOUNDS | ELI LILLY AND COMPANY | 2020-02-27 | — | — | US | disclosed |
| US-10370352-B2 | Cyclobutyl-imidazolidinone compounds | ELI LILLY AND COMPANY (US) | 2019-08-06 | — | — | US | disclosed |
| WO-2019047161-A1 | IMIDAZOLIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019047094-A1 | CYCLOBUTYL-IMIDAZOLIDINONE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019046186-A1 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20190071413-A1 | Cyclobutyl-Imidazolidinone Compounds | ELI LILLY AND COMPANY | 2019-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190071413-A1 | Cyclobutyl-Imidazolidinone Compounds | SLC10A1, CPT1A, SLC10A2 | KDM5A 535/4885RET 3653/4885MAP3K5 1968/4885 |
| US-20210087167-A1 | ASK1 INHIBITOR COMPOUNDS AND USES THEREOF | ATF1, MAP3K1, ROCK1 | KDM5A 1821/4885RET 1962/4885MAP3K5 20/4885 |
| US-20210061785-A1 | IMIDAZOLIDINE COMPOUNDS | SLC10A1, SLC10A2, CPT1A | KDM5A 428/4885RET 3696/4885MAP3K5 775/4885 |
| US-10370352-B2 | Cyclobutyl-imidazolidinone compounds | SLC10A1, CPT1A, SLC10A2 | KDM5A 535/4885RET 3653/4885MAP3K5 1968/4885 |
| US-11117891-B2 | Isoquinolin and naphthydrin compounds | SLC10A1, NQO1, SNX2 | KDM5A 2531/4885RET 4844/4885MAP3K5 2125/4885 |
| US-20200062751-A1 | ISOQUINOLIN AND NAPHTHYDRIN COMPOUNDS | SLC10A1, NQO1, NPC1 | KDM5A 2063/4885RET 4849/4885MAP3K5 2091/4885 |
| US-11124496-B2 | Imidazolidine compounds | SLC10A1, SLC10A2, CPT1A | KDM5A 428/4885RET 3696/4885MAP3K5 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.